Thr387

Site Information
RsMGtGDtPGLEVPs SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3204981

In vivo Characterization
Methods used to characterize site in vivo:	electrophoretic mobility shift ( 2 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ) , mutation of modification site ( 2 )
Disease tissue studied:	breast cancer ( 6 , 10 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, triple negative ( 3 ) , leukemia ( 23 ) , chronic myelogenous leukemia ( 23 ) , lung cancer ( 10 ) , non-small cell lung cancer ( 10 ) , lymphoma ( 2 ) , anaplastic large cell lymphoma ( 2 ) , prostate cancer ( 18 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 19 ) , BaF3 ('B lymphocyte, precursor') ( 2 ) , breast ( 3 ) , BT-549 (breast cell) ( 10 ) , Calu 6 (pulmonary) ( 10 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 11 ) , H2077 (pulmonary) ( 10 ) , H322M (pulmonary) ( 10 ) , HCC2279 (pulmonary) ( 10 ) , HCC827 (pulmonary) ( 10 ) , HEK293T (epithelial) ( 2 ) , HeLa (cervical) ( 4 , 9 , 12 , 17 , 20 , 22 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 6 ) , HMLER ('stem, breast cancer') ( 6 ) , JB-6 (lymphocyte) ( 2 ) , Jurkat (T lymphocyte) ( 8 , 13 , 14 , 15 , 16 , 21 ) , K562 (erythroid) ( 9 , 23 ) , LCLC-103H (pulmonary) ( 10 ) , liver ( 7 ) , LNCaP (prostate cell) ( 18 ) , LOU-NH91 (squamous) ( 10 ) , MDA-MB-231 (breast cell) ( 10 ) , MEF (fibroblast) ( 2 ) , NCI-H1648 (pulmonary) ( 10 ) , NCI-H2172 (pulmonary) ( 10 ) , NCI-H460 (pulmonary) ( 10 ) , TS (lymphocyte) ( 2 ) , Vero E6-S ('epithelial, kidney') ( 1 )

Upstream Regulation
Regulatory protein:	NPM-ALK (human) ( 2 )

Downstream Regulation
Effects of modification on NIPA:	intracellular localization ( 2 ) , molecular association, regulation ( 2 )
Effects of modification on biological processes:	cell growth, induced ( 2 )
Inhibit interaction with:	NPM-ALK (human) ( 2 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
2	Gengenbacher A, et al. (2019) Proteomic Phosphosite Analysis Identified Crucial NPM-ALK-Mediated NIPA Serine and Threonine Residues. Int J Mol Sci 20 31434245 Curated Info
3	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
4	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
5	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
6	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
7	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
8	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
9	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
10	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
11	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
12	Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540 21857030 Curated Info
13	Mulhern D (2011) CST Curation Set: 12641; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
14	Mulhern D (2011) CST Curation Set: 12642; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
15	Guo A (2011) CST Curation Set: 12017; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
16	Guo A (2011) CST Curation Set: 12024; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
17	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
18	Chen L, Giorgianni F, Beranova-Giorgianni S (2010) Characterization of the phosphoproteome in LNCaP prostate cancer cells by in-gel isoelectric focusing and tandem mass spectrometry. J Proteome Res 9, 174-8 20044836 Curated Info
19	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
20	Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8 19276368 Curated Info
21	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
22	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
23	Stokes M (2008) CST Curation Set: 4392; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info